A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).
Checked against the public recordLast updated May 12, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Hoffmann-La Roche
- Interventions being studied
- Drug: Atezolizumab; Drug: Cobimetinib; Drug: RO6958688; Drug: Docetaxel; Drug: CPI-444; Drug: Pemetrexed; Drug: Carboplatin; Drug: Gemcitabine; Drug: Linagliptin; Drug: Tocilizumab; Drug: Ipatasertib; Drug: Bevacizumab; Drug: Sacituzumab Govitecan; Other: Radiation; Drug: Evolocumab; Drug: Tiragolumab; Drug: XL092; Drug: Camonsertib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
General Inclusion Criteria * Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1 * Life expectancy greater than or equal to 3 months * Histologically or cytologically confirmed metastatic, non-squamous or squamous Non-Small Cell Lung Cancer (NSCLC) * Measurable disease (at least one target lesion) * Adequate hematologic and end-organ function * Tumor accessible for biopsy * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating eggs as outlined for each specific treatment arm * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm Inclusion Criteria for Cohort 1 * No prior systemic therapy for metastatic NSCLC * High tumor PD-L1 expression, defined as Tumor Proportion Score (TPS) or TCs \>= 50% or TC3 Inclusion Criteria for Cohort 2 \- Disease progression during or following treatment for metastatic or locally advanced, inoperable NSCLC Exclusion Criteria * Prior allogeneic stem cell or solid organ transplantation * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * History of leptomeningeal disease * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan * History of malignancy other than NSCLC within 2 years prior to screening * Active tuberculosis * Severe infection within 4 weeks prior to initiation of study treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Comprehensive Cancer Centers of Nevada (CCCN) - Central ValleyLas Vegas, Nevada
- Columbia University Medical CenterNew York, New York
- University Hospitals Case Medical CenterCleveland, Ohio
- SCRI Oncology PartnersNashville, Tennessee
- Blacktown HospitalBlacktown, New South Wales
- Peter Mac Callum Cancer CenterEast Melbourne, Victoria
- Centre Georges Francois LeclercDijon
- Centre Léon BérardLyon
- Hopital de la TimoneMarseille
- Institut Régional du Cancer de MontpellierMontpellier
- Institut De Cancerologie De L'OuestSaint-Herblain
- Institut Universitaire du Cancer de Toulouse-OncopoleToulouse
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2026. Always confirm current availability with the study team.